N@N

CNK, AEA, SGEN, TIF, Expected to Trade Lower After Bearish Insider Trading

^{Published on 2011-06-23 05:40:41 - WOPRAI}
 

June 23, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Lower in the next 6 months. CINEMARK HOLDINGS, INCORPORATION. (NYSE:CNK), ADVANCE AMERICA, CASH ADVANCE CENTERS, INC. (NYSE:AEA), SEATTLE GENETICS, INC. (NASDAQ:SGEN), TIFFANY & CO (NYSE:TIF) are all expected to go Lower as Sell signals have been generated by top insider trading patterns. The most important data elements considered when performing insider analysis are: Insiders Track Record - An insiders track record is best summarized by the Insider Score which ranges from 1 (least predictive) to 100 (most predictive) based on prior trading performance. In addition, the actual returns following the insiders prior trades are included to determine the potential magnitude of future returns. Insiders Role - Trades by higher-level insiders are generally more predictive than trades by lower level insiders. Higher-level insiders to include Chairman (CB), Chief Executive Officer (CEO), President (P), Chief Financial Officer (CFO), and Vice Chairman (VC).

The chart below displays the stocks expected to go Lower along with the insider name, position, predictive insider score, 6 month expected return and number of trading decisions included in the score.

     Symbol     Company Name                        Insider Name                        Role        Shares         Insider Score     Avg 6 Month Return     # of Dec. 
     CNK        CINEMARK HOLDINGS, INCORPORATION.     Copple, Robert D                    CFO         45,000         77                -16.6%                 4         
     AEA        ADVANCE AMERICA, CASH ADVANCE CENTERS, INC.     Johnson, George D Jr                B           45,100         80                -19.0%                 9         
     SGEN       SEATTLE GENETICS, INC.              Dobmeier, Eric L                    CO          13,385         96                -18.3%                 10        
     TIF        TIFFANY & CO                        Quinn, James E                      P           115,000        81                -3.1%                  35        

CINEMARK HOLDINGS, INCORPORATION. (NYSE:CNK) - Cinemark Holdings, Inc. and subsidiaries engage in the motion picture exhibition business. As of December 31, 2009, the company operated 424 theatres and 4,896 screens in the United States, Canada, and Latin America. The company also manages theatres in the United States, Brazil, and Colombia. Cinemark Holdings is headquartered in Plano, Texas.

ADVANCE AMERICA, CASH ADVANCE CENTERS, INC. (NYSE:AEA) - Advance America, Cash Advance Centers, Inc. provides cash advance services in the United States, the United Kingdom, and Canada. The company offers cash advance services, which include cash advances, installment loans, and lines of credit. Its cash advances are small-denomination, short-term, and unsecured advances that are due on the customer's next payday. The company also provides check cashing services at state authorized rates; pre-paid debit cards and money orders; and money transmission and bill payment services. It primarily serves middle-income working individuals. As of December 31, 2009, Advance America, Cash Advance Centers, Inc. operated 2,553 centers in the United States under the Advance America and National Cash Advance brand names; and 21 centers in the United Kingdom and 13 centers in Canada under the National Cash Advance brand name. It also had 71 limited licensees in the United Kingdom. The company was founded in 1997 and is headquartered in Spartanburg, South Carolina.

SEATTLE GENETICS, INC. (NASDAQ:SGEN) - Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The companys other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

TIFFANY & CO (NYSE:TIF) - Tiffany & Co., through its subsidiaries, engages in the design, manufacture, and retail of fine jewelry. Its jewelry products include gemstone jewelry, gemstone band rings, diamond rings, wedding bands for brides and grooms, non-gemstone, gold or platinum jewelry, and sterling silver jewelry. The company also offers TIFFANY & CO. brand merchandise, including timepieces and clocks; sterling silver merchandise, including flatware, hollowware, trophies, key holders, picture frames, and desk accessories; crystal, glassware, china, and other tableware; custom engraved stationery; writing instruments; eyewear; leather goods; and fashion accessories. In addition, it provides fragrance products sold under the trademarks, including TIFFANY, PURE TIFFANY, and TIFFANY FOR MEN. The company serves its customers through retail sales, Internet and catalog sales, business to business sales, and wholesale distribution primarily in the Americas, the Asia-Pacific, and Europe. It also sells its products through TIFFANY & CO. stores, as well as through department store boutiques in Japan. As of January 31, 2010, Tiffany & Co. operated approximately 220 retail stores worldwide. The company was founded in 1837 and is based in New York, New York.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

Insider Trading tracks all insider trades and selects those insider buys that predict higher moves and insider sales that predict lower moves.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net